OXFORD BIODYNAMICS PLC — Director's Dealing 2020

Mar 2, 2020

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 7389E

Oxford BioDynamics PLC

02 March 2020

2 March 2020

Oxford BioDynamics Plc

("OBD" or the "Company" and, together with its subsidiaries, the "Group")

Correction - PDMR Dealing

Oxford BioDynamics Plc (AIM: OBD) announces that the "PDMR Dealing" announcement released on 26 February 2020 under RNS number 2201E has been amended as follows:

Shares were purchased by Vulpes Testudo Fund, and not Vulpes Life Sciences Fund as originally stated.

Following this transaction, Vulpes Testudo Fund was interested in 38,963 Ordinary Shares, representing 0.04% of the Company's current issued share capital. Through the holdings of Vulpes Life Sciences Fund and Vulpes Testudo Fund, Stephen Diggle was interested in a total of 11,849,633 Ordinary Shares, representing approximately 12.8% of the Company's current issued share capital.

All other details remain unchanged. The full amended text is shown below.

PDMR Dealing

Oxford BioDynamics Plc (AIM: OBD) announces that it has today received notice that Vulpes Testudo Fund, which is controlled by Non-Executive Director, Stephen Diggle, has purchased 2,594 Ordinary Shares of 1 pence each at a price of 84.5p per share.

Following this transaction, Vulpes Testudo Fund is interested in 38,963 Ordinary Shares, representing 0.04% of the Company's current issued share capital. Through the holdings of Vulpes Life Sciences Fund and Vulpes Testudo Fund, Stephen Diggle is interested in 11,849,633 Ordinary Shares, representing approximately 12.8% of the Company's current issued share capital.

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further details:

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Stephen Diggle

2

Reason for the notification

a)

Position/status 

Director/PDMR

b)

Initial notification/ Amendment 

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Oxford BioDynamics Plc 

b)

LEI

2138005Y1TK258O5U928

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code 

Ordinary Shares of 1 pence each

ISIN:   GB00BD5H8572

b)

Nature of the transaction

Acquisition of ordinary shares

c)

Price(s) and volume(s)

Price(s)	Volume(s)
0.792	38,963

d)

Aggregated information

- Aggregated volume

- Price

Price	Volume
0.792	38,963

e)

Dates of the transactions

25 February 2020

f)

Place of the transaction

Outside a trading venue

For further details please contact:

Oxford BioDynamics Plc Christian Hoyer Millar, CEO Paul Stockdale, CFO	+44 (0)1865 518910
Shore Capital Nominated Adviser and Broker Stephane Auton Edward Mansfield	+44 (0)20 7408 4090
FTI Consulting Financial Public Relations Adviser Natalie Garland-Collins	+44 (0)20 3727 1000

Notes for Editors

About Oxford BioDynamics Plc

Oxford BioDynamics Plc (AIM: OBD) ("Oxford BioDynamics") is a biotechnology company focused on the discovery and development of epigenetic biomarkers for use within the pharmaceutical and biotechnology industry.

The Company's award-winning, proprietary technology platform, EpiSwitch™, aims to accelerate the drug discovery and development process, improve the success rate of therapeutic product development and take advantage of the increasing importance of personalised medicine.

In particular, EpiSwitch™ can reduce time to market, failure rates and the costs at every stage of drug discovery. Additionally, the technology provides significant insights into disease mechanisms for drug discovery and product re‐positioning programmes and enables the personalisation of therapeutics for patients in the context of challenging pricing environments where improved clinical outcomes are critical.

In April 2019, Oxford BioDynamics received the Queen's Award for Enterprise: Innovation. The Queen's Awards for Enterprise are the most prestigious awards for UK businesses.

Oxford BioDynamics is headquartered in the UK, and listed on the London Stock Exchange's AIM under the ticker "OBD". For more information please visit www.oxfordbiodynamics.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

DSHSSMFIEESSEDD